Havana, February 8 (RHC)-- Cuban President Miguel Díaz-Canel ratified Tuesday, together with Cuban scientists, that the forecasts for COVID-19 cases are favorable for all provinces and the epidemic remains under control.
According to the official Twitter profile of the Presidency, the meeting also evaluated the encouraging results of the clinical studies of the Jusvinza drug for the treatment of rheumatoid arthritis, a disease that affects more than 136,000 Cubans.
According to the official information, the novel drug produced by Cuba's Center for Genetic Engineering and Biotechnology -CIGB-, has also shown high efficacy in patients with COVID-19.
Jusvinza is Cuba's first therapeutic product based on synthetic peptide, it achieves improvements in ventilatory parameters and inflammation markers, which leads to the recovery of people complicated by the pandemic caused by the SARS-CoV-2 virus.
At a similar meeting last October, Dr. María del Carmen Domínguez presented the results of the application of Jusvinza (CIGB-258), which, she said, has led to high levels of recovery in critical, severe and high-risk patients.
The same positive effects were achieved with the application of this drug to pregnant women (to reduce extremely severe maternal morbidity and maternal mortality) and in pediatric cases, he informed.
Jusvinza could be used against rheumatoid arthritis, juvenile idiopathic arthritis, which affects children, and sepsis, specifically in community pneumonia.
At another time, the Cuban president headed the Temporary Working Group for the confrontation of COVID-19 and evaluated the sustained decrease of active cases in all territories, according to the Presidency.